ArticleThe Analyst2020
Paper-based microchip electrophoresis for point-of-care hemoglobin testing.
Article in The Analyst, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Assessing the Predictive Power of the Hemoglobin/Red Cell Distribution Width Ratio in Cancer: A Systematic Review and Future Directions.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Validation of Gazelle Microchip Electrophoresis for Premarital Hemoglobinopathy Screening in Türkiye.EJHaem · 2026Article
- Acoustic probing of new biomarkers for rapid sickle cell disease screening.Lab on a chip · 2026Article
- Iron Deficiency Diagnosis in Sub-Saharan Africa: Challenges, Barriers, and Opportunities.Anemia · 2026Review
- Validation of the Gazelle point-of-care device for hemoglobin variant analysis in a predominantly pediatric population: performance comparison with conventional electrophoresis.Frontiers in medicine · 2026Article
- Integration of newborn screening for sickle cell disease into primary health care in Bukavu, Democratic Republic of the Congo: a pilot study.BMC primary care · 2025Article
- Emerging Technologies and Advanced Strategies in Hemoglobin Defect Screening.Journal of clinical medicine · 2025Review
- Know your blood: Addressing barriers to preconceptual screening for sickle cell disease.HemaSphere · 2025Article
- PolyJet Three-dimensional-Printed Microchip Devices With Integrated Carbon Electrodes for Neurotransmitter Analysis.Journal of separation science · 2025Article
- Advancement of microchip electrophoresis coupled with capacitively coupled contactless conductivity detection-from design to application (2018-2024).Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Review
- Evaluation of low-cost techniques to detect sickle cell disease and β-thalassemia: an open-label, international, multicentre study.The Lancet regional health. Southeast Asia · 2025Article
- Demonstrating public health impacts of translational science at the clinical and translational science collaborative (CTSC) of northern Ohio: a mixed-methods approach using the translational science benefits model.Frontiers in public health · 2025Article
- Newborn screening initiatives for sickle cell disease in Africa.Hematology. American Society of Hematology. Education Program · 2024Review
- A multiplexed, allele-specific recombinase polymerase amplification assay with lateral flow readout for sickle cell disease detection.Lab on a chip · 2024Article
- Assessment of diagnostic accuracy of Gazelle: A point-of-care testing device for screening β-thalassemia trait.The Indian journal of medical research · 2024Review
- Differential sensitivity to hypoxia enables shape-based classification of sickle cell disease and trait blood samples at point of care.Bioengineering & translational medicine · 2024Article
- Review on Microreactors for Photo-Electrocatalysis Artificial Photosynthesis Regeneration of Coenzymes.Micromachines · 2024Review
- Regional Prevalence of Hemoglobin C Across Saudi Arabia: An Epidemiological Survey.Journal of epidemiology and global health · 2024Article
- Point-of-Care Diagnostic Test for Beta-Thalassemia.Biosensors · 2024Article
- Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 14 institutions in 6 countries.
Funding
Abstract
Nearly 7% of the world's population live with a hemoglobin variant. Hemoglobins S, C, and E are the most common and significant hemoglobin variants worldwide. Sickle cell disease, caused by hemoglobin S, is highly prevalent in sub-Saharan Africa and in tribal populations of Central India. Hemoglobin C is common in West Africa, and hemoglobin E is common in Southeast Asia. Screening for significant hemoglobin disorders is not currently feasible in many low-income countries with the high disease burden. Lack of early diagnosis leads to preventable high morbidity and mortality in children born with hemoglobin variants in low-resource settings. Here, we describe HemeChip, the first miniaturized, paper-based, microchip electrophoresis platform for identifying the most common hemoglobin variants easily and affordably at the point-of-care in low-resource settings. HemeChip test works with a drop of blood. HemeChip system guides the user step-by-step through the test procedure with animated on-screen instructions. Hemoglobin identification and quantification is automatically performed, and hemoglobin types and percentages are displayed in an easily understandable, objective way. We show the feasibility and high accuracy of HemeChip via testing 768 subjects by clinical sites in the United States, Central India, sub-Saharan Africa, and Southeast Asia. Validation studies include hemoglobin E testing in Bangkok, Thailand, and hemoglobin S testing in Chhattisgarh, India, and in Kano, Nigeria, where the sickle cell disease burden is the highest in the world. Tests were performed by local users, including healthcare workers and clinical laboratory personnel. Study design, methods, and results are presented according to the Standards for Reporting Diagnostic Accuracy (STARD). HemeChip correctly identified all subjects with hemoglobin S, C, and E variants with 100% sensitivity, and displayed an overall diagnostic accuracy of 98.4% in comparison to reference standard methods. HemeChip is a versatile, mass-producible microchip electrophoresis platform that addresses a major unmet need of decentralized hemoglobin analysis in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.